MX349653B - Vacunógeno de ospc quimérico polivalente y antígeno de diagnóstico. - Google Patents
Vacunógeno de ospc quimérico polivalente y antígeno de diagnóstico.Info
- Publication number
- MX349653B MX349653B MX2013004482A MX2013004482A MX349653B MX 349653 B MX349653 B MX 349653B MX 2013004482 A MX2013004482 A MX 2013004482A MX 2013004482 A MX2013004482 A MX 2013004482A MX 349653 B MX349653 B MX 349653B
- Authority
- MX
- Mexico
- Prior art keywords
- diagnostic antigen
- polyvalent chimeric
- chimeric ospc
- vaccinogen
- ospc vaccinogen
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 101710105711 Outer surface protein C Proteins 0.000 abstract 3
- 206010061591 Borrelia infection Diseases 0.000 abstract 1
- 208000016604 Lyme disease Diseases 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/20—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39487710P | 2010-10-20 | 2010-10-20 | |
| PCT/US2011/056854 WO2012054580A2 (en) | 2010-10-20 | 2011-10-19 | Polyvalent chimeric ospc vaccinogen and diagnostic antigen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013004482A MX2013004482A (es) | 2015-03-09 |
| MX349653B true MX349653B (es) | 2017-07-31 |
Family
ID=45975855
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017000917A MX388945B (es) | 2010-10-20 | 2011-10-19 | Vacunogeno de ospc quimerico polivalente y antigeno de diagnostico. |
| MX2013004482A MX349653B (es) | 2010-10-20 | 2011-10-19 | Vacunógeno de ospc quimérico polivalente y antígeno de diagnóstico. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017000917A MX388945B (es) | 2010-10-20 | 2011-10-19 | Vacunogeno de ospc quimerico polivalente y antigeno de diagnostico. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8808705B2 (enExample) |
| EP (2) | EP2630162A4 (enExample) |
| JP (1) | JP2013542942A (enExample) |
| KR (1) | KR20130125771A (enExample) |
| CN (1) | CN103339151A (enExample) |
| AU (1) | AU2011317105B2 (enExample) |
| BR (1) | BR112013009588A2 (enExample) |
| CA (1) | CA2815279C (enExample) |
| MX (2) | MX388945B (enExample) |
| WO (1) | WO2012054580A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY34745A (es) * | 2012-04-18 | 2013-11-29 | Zoetis Llc | Vacunas y procedimientos para tratar la enfermedad de lyme en perros |
| US9562079B2 (en) | 2012-04-18 | 2017-02-07 | Zoetis Services Llc | Vaccines and methods to treat lyme disease in dogs |
| CZ2014320A3 (cs) * | 2014-05-09 | 2015-11-18 | VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. | Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy |
| EP3204404A4 (en) * | 2014-10-08 | 2018-06-06 | Virginia Commonwealth University | Stage specific diagnostic antigens, assay and vaccine for lyme disease |
| EP3359558B1 (en) * | 2015-10-06 | 2023-12-13 | Bio-Rad Laboratories, Inc. | Borrelia immunoassays and materials therefor |
| WO2025015077A1 (en) | 2023-07-10 | 2025-01-16 | Dynavax Technologies Corporation | Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6872550B1 (en) | 1991-07-11 | 2005-03-29 | Baxter Vaccine Ag | Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens |
| US7008625B2 (en) * | 1993-11-01 | 2006-03-07 | Research Foundation Of The State University Of New York | Recombinant constructs of Borrelia burgdorferi |
| US6248562B1 (en) | 1993-11-01 | 2001-06-19 | Research Foundation State University Of New York | Chimeric proteins comprising borrelia polypeptides and uses therefor |
| ES2302385T3 (es) * | 1998-07-31 | 2008-07-01 | Gundersen Lutheran Medical Foundation, Inc. | Uso de epitopo(s) borrelicida(s) de la proteina c de superficie externa de borrelia burgdorferi como vacuna. |
| DE60030859T2 (de) * | 1999-06-18 | 2007-06-14 | The Research Foundation Of State University Of New York | Gruppen von borrelia burgdorferi, die lyme krankheit verursachen |
| US8821893B2 (en) * | 2004-07-02 | 2014-09-02 | Bio Peptides, Corp. | Oral vaccine for Borrelia |
| US7794727B2 (en) * | 2005-11-29 | 2010-09-14 | Virginia Commonwealth University | Polyvalent chimeric OspC vaccinogen and diagnostic antigen |
| CA2668405C (en) * | 2006-11-03 | 2015-05-05 | Schering-Plough Ltd. | Canine lyme disease vaccine |
| WO2009135118A2 (en) * | 2008-05-02 | 2009-11-05 | Virginia Commonwealth University | Lyme disease vaccine |
-
2011
- 2011-10-19 EP EP11835051.1A patent/EP2630162A4/en not_active Withdrawn
- 2011-10-19 MX MX2017000917A patent/MX388945B/es unknown
- 2011-10-19 JP JP2013535034A patent/JP2013542942A/ja active Pending
- 2011-10-19 EP EP15199992.7A patent/EP3029073B1/en not_active Not-in-force
- 2011-10-19 MX MX2013004482A patent/MX349653B/es active IP Right Grant
- 2011-10-19 CA CA2815279A patent/CA2815279C/en active Active
- 2011-10-19 AU AU2011317105A patent/AU2011317105B2/en not_active Ceased
- 2011-10-19 WO PCT/US2011/056854 patent/WO2012054580A2/en not_active Ceased
- 2011-10-19 US US13/879,848 patent/US8808705B2/en not_active Expired - Fee Related
- 2011-10-19 KR KR1020137012622A patent/KR20130125771A/ko not_active Withdrawn
- 2011-10-19 BR BR112013009588A patent/BR112013009588A2/pt not_active IP Right Cessation
- 2011-10-19 CN CN2011800611724A patent/CN103339151A/zh active Pending
-
2014
- 2014-08-01 US US14/449,721 patent/US9556239B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103339151A (zh) | 2013-10-02 |
| JP2013542942A (ja) | 2013-11-28 |
| CA2815279C (en) | 2021-04-13 |
| EP3029073A1 (en) | 2016-06-08 |
| CA2815279A1 (en) | 2012-04-26 |
| KR20130125771A (ko) | 2013-11-19 |
| WO2012054580A3 (en) | 2012-08-16 |
| US9556239B2 (en) | 2017-01-31 |
| BR112013009588A2 (pt) | 2017-10-10 |
| MX2013004482A (es) | 2015-03-09 |
| US20130266606A1 (en) | 2013-10-10 |
| WO2012054580A2 (en) | 2012-04-26 |
| AU2011317105A1 (en) | 2013-05-23 |
| US20150064208A1 (en) | 2015-03-05 |
| EP2630162A4 (en) | 2014-04-30 |
| EP2630162A2 (en) | 2013-08-28 |
| EP3029073B1 (en) | 2019-09-04 |
| MX388945B (es) | 2025-03-20 |
| AU2011317105B2 (en) | 2018-04-05 |
| US8808705B2 (en) | 2014-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007065098A3 (en) | Polyvalent chimeric ospc vaccinogen and diagnostic antigen | |
| MY165038A (en) | Humanized antibodies that recognize alpha-synuclein | |
| MX349653B (es) | Vacunógeno de ospc quimérico polivalente y antígeno de diagnóstico. | |
| BR112014019901A2 (pt) | proteínas de fator viii recombinante | |
| CR20130016A (es) | ANTICUERPOS PEPTIDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
| BR112014018005A2 (pt) | uso de complexo não covalente imobilizado e variante de região fc de isotipo igg1 humano | |
| CL2014000679A1 (es) | Anticuerpo de unión a tau; vector; célula hospedadora; hibridoma; péptido que comprende epítope de tau; composición farmacéutica que comprende al anticuerpo o al péptido de tau; dispositivo médico para administrarlos; uso para tratar, prevenir o diagnosticar enfermedad de alzheimer o tautología relacionada; y método para producir anticuerpo | |
| CR20130126A (es) | Anticuerpos anti-ox40 y métodos de uso de los mismos | |
| CR20120087A (es) | Anticuerpos del antígeno carcinoembrionario (cea) | |
| TN2012000167A1 (en) | Human il-23 antigen binding proteins | |
| ZA201304459B (en) | Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof | |
| EP4272750A3 (en) | Protein antigens that provide protection against pneumococcal colonization and/or disease | |
| WO2016176624A3 (en) | Porcine pestvirus, vaccines, and assays | |
| MX2014009845A (es) | Vectores poxvirales recombinantes que expresan proteinas tanto de rabia como de ox40, y vacunas hechas a partir de los mismos. | |
| IN2012DN06309A (enExample) | ||
| CL2012003458A1 (es) | Vector que comprende un polipeptido antigénico de campylobacter; composicion farmacéutica que comprende dicho vector; uso del vector para mejorar respuesta inmune del sujeto al polipéptido antigénico. | |
| EP3835425A4 (en) | Recombinant vector for producing antigen for diagnosis of african swine fever and use thereof | |
| NZ594198A (en) | Neil3 peptides and vaccines including the same | |
| MX2021010021A (es) | Proteínas sintéticas autoensamblables. | |
| IL210861A0 (en) | Melk epitope peptides and vaccines containing the same | |
| EA200970731A1 (ru) | Рекомбинантные антигены цитомегаловируса человека (hcmv) | |
| EP2528939A4 (en) | RECOMBINANT PROTEINS FOR USE IN VACCINES, ANTIBODIES TO THESE PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC PROCEDURES THEREWITH | |
| PH12014500544B1 (en) | Dengue-virus serotype neutralizing antibodies | |
| NZ610460A (en) | Immunoglobulin cleavage fragments vaccine compositions | |
| WO2012088125A3 (en) | Methods and compositions of protein antigens for the diagnosis and treatment of toxoplasma gondii infections and toxoplasmosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |